SANDPIPER (NCT02340221), which was a double‐blind, placebo‐controlled, randomized phase III study, assessed the combination of taselisib plus fulvestrant in HR+/HER2−, PIK3CA‐MUT locally advanced or metastatic BC postmenopausal patients with disease recurrence or progression during or after an AI. The gene discussed is PIK3CA; the disease is breast cancer.